ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.
Also called NCT01848639
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 823 participants
- Sponsor
- Registry
-
NCT01848639
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, France, Monaco
- Registry status
- Completed
Technical summary
Registry record NCT01848639. Randomized; triple masking; primary purpose treatment. Start 2013-06 (actual); primary completion 2022-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial
- Acronym
- ALCHEMIST
- Condition
- End Stage Renal Failure on Dialysis
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Hospital, Brest
- Collaborator
- Central Hospital, Nancy, France
- Collaborator
- Institut National de la Santé Et de la Recherche Médicale, France
Record details
- Record id
cardio:ct-nct01848639- Content hash
8416b81a57bba208b9cd7451ee7128f6a2d5de928b42ae8ac4e944016bb22449